Your Teen's A1C Came Back High. Now What? A Pediatric Obesity Specialist's Guide for the Lab-Portal Moment

If you are reading this after seeing your teen's A1C in the patient portal, take a breath. You have time. An A1C of 5.7 to 6.4 percent is the prediabetes range, and it is treatable. The next steps are confirming the result, getting the full metabolic and liver panel, and starting the intensive lifestyle treatment that the American Academy of Pediatrics recommends as the first-line foundation.

What an abnormal A1C result means in a teenager

An A1C of 5.7 to 6.4 percent sits in the prediabetes range. The diagnostic standard is a confirmation test on a different day before treatment starts. A repeat A1C, a fasting glucose, or an oral glucose tolerance test (OGTT) all qualify.

A1C is a blood test that estimates average blood sugar over the past three months. It is the standard screening test for prediabetes and type 2 diabetes in children, teens, and adults.

The reference ranges your portal will show map to the American Diabetes Association cutoffs the AAP applies to pediatric screening (ADA Standards of Care 2026). Below 5.7 percent is normal. Between 5.7 and 6.4 percent is the prediabetes range. At or above 6.5 percent is the type 2 diabetes range.

The pediatric-evidence caveat is worth stating plainly. These cutoffs were established primarily in adult populations and extended to pediatric screening. The evidence base for the 5.7 to 6.4 percent range as a predictor of progression in adolescents specifically is still accumulating. That is one reason the diagnostic standard pairs a repeat A1C with a fasting glucose or OGTT before formal diagnosis.

What the patient portal often does NOT show: whether the test was screening or diagnostic, the fasting status, and the recommended confirmation pathway. Those are the first questions to ask the pediatrician.

What to do tonight, tomorrow morning, and at the appointment

Take three concrete steps tonight, call the pediatrician tomorrow morning, and bring a written list of questions to the visit.

Tonight (the next few hours)

1. Take a breath. An abnormal A1C is not a diabetes diagnosis. It is the start of a diagnostic and treatment conversation.
2. Screenshot or save the full lab panel. Include the A1C, fasting glucose if drawn, fasting insulin if drawn, the full liver panel (ALT, AST), and the lipid panel.
3. Note the date of the test, whether your teen was fasting, and any meals or activity in the 12 hours before the draw. These affect interpretation.
4. Do not make abrupt diet or activity changes tonight. Sudden restriction is not the goal. Sustained, supported behavior change is.
5. Do not start any over-the-counter blood sugar supplements. None have meaningful pediatric evidence, and they can interfere with diagnostic workup.

Tomorrow morning

1. Call the pediatrician's office. Ask for the soonest available appointment. Say: "I would like to discuss my teen's abnormal A1C result."
2. If the appointment is more than two weeks out, ask whether the office can order the confirmation labs before the visit. That turns the appointment into a treatment-planning conversation.
3. Ask whether the office recommends a pediatric endocrinology or pediatric obesity medicine referral.
4. Begin writing down your appointment questions. The next section is the list.

At the pediatrician appointment (the questions to ask)

Print this list, screenshot it, or paste it into your phone notes. Bring it to the appointment.

1. Is this a screening A1C or a diagnostic A1C? Should we repeat it and add a fasting glucose or OGTT to confirm the prediabetes diagnosis before starting treatment?
2. What is the full metabolic and liver workup you recommend? Have you ordered fasting insulin, the fasting lipid panel, ALT and AST, vitamin D, and a thyroid panel?
3. If the ALT is also flagged, are we evaluating for MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD)?
4. What IHBLT-equivalent intensive lifestyle program is available in our area or by telehealth? The AAP recommends a program of at least 26 contact hours over 3 to 12 months.
5. If we start an intensive lifestyle program for 3 to 6 months and re-test, what A1C trajectory would trigger adding metformin? What is the threshold for considering a GLP-1?
6. Under what conditions would you refer to a pediatric obesity medicine specialist or a pediatric endocrinologist for the medication conversation?
7. Should my teen be screened for sleep apnea, hypertension, and PCOS in female teens? These often co-occur with prediabetes.
8. What mental-health and eating-disorder screening is part of the evaluation? Eating-disorder screening is part of the AAP standard for obesity workup.

What about the ALT result. Is this also a liver problem?

A flagged ALT may signal MASLD, the new name for NAFLD. It commonly co-occurs with teen prediabetes because both share the same underlying physiology.

ALT stands for alanine aminotransferase, a liver enzyme. An elevated ALT can indicate MASLD, the new name for what was called NAFLD (non-alcoholic fatty liver disease). The nomenclature changed in 2023 after a multisociety Delphi consensus process led by AASLD, EASL, and ALEH (Rinella ME et al., Hepatology 2023). Both terms are still in active use across labs and clinics.

MASLD and prediabetes share the same root cause: insulin resistance. They frequently co-occur in adolescents with obesity. NASPGHAN recommends ALT screening in this group, and the AAP CPG references the same workup (Vos MB et al., JPGN 2017).

The ALT cutoffs used for pediatric screening are sex-adjusted. NASPGHAN's referenced upper limits are approximately 22 U/L for adolescent females and 26 U/L for adolescent males. Your lab's reference range may differ, which is why the clinical interpretation belongs with the pediatrician.

The treatment overlap is the encouraging part. The IHBLT lifestyle foundation that the AAP recommends for prediabetes also drives ALT improvement in MASLD. Weight reduction of 7 to 10 percent has been associated with measurable ALT and liver-fat reduction in adolescents with MASLD.

What the AAP recommends. The stepped-care framework

The AAP 2023 CPG outlines a graduated framework: evaluation, then IHBLT, then pharmacotherapy consideration alongside IHBLT, then surgical referral for severe cases.

The CPG's evaluation recommendation in the prediabetes context calls for a full metabolic and comorbidity workup (the cross-link page details the lab and screening list).

The CPG's IHBLT recommendation (KAS 5) is intensive lifestyle treatment for all children age 6 and older with overweight or obesity (BMI at or above the 85th percentile). The 26-contact-hour bar over 3 to 12 months is the evidence-based intensity threshold.

The CPG's pharmacotherapy recommendation is consideration of pharmacotherapy alongside IHBLT for adolescents 12 and older with BMI at or above the 95th percentile, with shared decision-making. It is paired with IHBLT, not a substitute for it.

Surgical evaluation is reserved for adolescents 13 and older with severe obesity; the cross-link page covers the full criteria.

For the full framework walkthrough, see our parent summary of the AAP 2023 obesity guidelines.

The lifestyle-first treatment path (IHBLT)

IHBLT is the AAP-recommended first-line foundation for teen prediabetes. It calls for at least 26 contact hours over 3 to 12 months.

IHBLT combines nutrition counseling, physical activity coaching, family-system support, and behavioral health components, delivered intensively. It is not "eat less, move more."

In practice, an IHBLT program involves regular touchpoints with a clinician, family-aware nutrition and activity coaching, motivational interviewing, and comorbidity-aware planning where the prediabetes overlay shapes the nutrition guidance.

The expected lab trajectory: at 3 to 6 months, with 7 to 10 percent weight reduction, the published evidence (adult Diabetes Prevention Program data extended to pediatric intensive-lifestyle cohorts) supports A1C improvement of about 0.2 to 0.5 percentage points and ALT improvement in MASLD cases. Individual response varies. The trajectory itself is the metric that informs whether to add pharmacotherapy at the re-test.

The AAP CPG itself names the access reality. Programs at or above 26 contact hours are hard to access in most pediatric primary-care settings. See our lifestyle-only program overview for one telehealth model designed to close that gap.

When the AAP says to consider medication. Metformin, GLP-1, and the evidence base

The CPG allows pharmacotherapy consideration alongside IHBLT for adolescents 12 and older with BMI at or above the 95th percentile. The decision is paired with IHBLT and made through shared decision-making.

The CPG framing is precise. Medication consideration is recommended alongside IHBLT for adolescents 12 and older with BMI at or above the 95th percentile. The CPG does not name a specific medication. Clinical judgment determines first-line selection. Medication is not stand-alone, not first-line, and not recommended for children under 12.

GLP-1 receptor agonists in adolescents include liraglutide (Saxenda, FDA-approved for ages 12 and older in 2020) and semaglutide (Wegovy, approved in 2022), with semaglutide carrying the larger BMI effect per the STEP TEENS trial (Weghuber D et al., NEJM 2022;387:2245-2257). Both drugs carry an FDA boxed warning for medullary thyroid carcinoma seen in rodent studies, and both are contraindicated in adolescents with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Your pediatrician or pediatric obesity medicine specialist will screen for this history before prescribing. STEP TEENS demonstrated substantial BMI reduction in adolescents 12 to 17 with obesity treated with semaglutide versus placebo. A 2025 secondary analysis added cardiometabolic and glycemic detail (Arslanian SA et al., Diabetes Care 2025). GLP-1 is increasingly considered for adolescents who do not respond to metformin plus IHBLT, again with shared decision-making.

Honest framing on what the evidence does NOT yet show: long-term post-medication A1C trajectory in adolescents specifically is still accumulating. The CPG acknowledges this is an evolving area, so the medication conversation has to include the durability question.

For more on the medication pathway, see our Wegovy for teens hub and the Wegovy safety overview.

How Blueberry Balance implements the AAP framework for teen prediabetes

Blueberry Balance is one operational model for the AAP CPG stepped-care framework. It is built around a DABOM-led specialist evaluation and an unlimited-coaching IHBLT base layer.

To hold the framing precisely: Balance is not what the AAP recommends. Balance is one way to implement what the AAP recommends.

The IHBLT base layer combines unlimited asynchronous and synchronous coaching, family-system support, nutrition counseling, and physical activity coaching. It is designed to reach the 26-contact-hour intensity bar in a way traditional weekly primary-care visits do not.

The specialist evaluation layer is led by Dr. Makia Powers, DABOM, the specialty credential the AAP CPG references for adolescent pharmacotherapy management. Comorbidity evaluation, shared decision-making, and lab and biometric monitoring during any pharmacotherapy titration are built into the cadence.

The stepped-care pharmacotherapy layer follows the CPG. GLP-1 is considered per CPG-aligned indications when IHBLT does not produce the indicated trajectory.

Balance does not perform or recommend metabolic and bariatric surgery. Surgical evaluation requires a comprehensive in-person multidisciplinary center, and Balance refers to that pathway when clinically indicated. Balance also works alongside, not in place of, in-person pediatric primary care.

Frequently asked questions

Can teen prediabetes be reversed?

Yes, in many cases. Published pediatric cohorts show that a meaningful share of adolescents with prediabetes return to a normal A1C with sustained intensive lifestyle treatment, especially when 7 to 10 percent weight reduction is achieved over 3 to 12 months. The trajectory matters more than any single lab value. Prediabetes can return if the underlying pattern reverses, which is why the AAP CPG frames treatment as ongoing stepped-care.

Is an A1C of 5.9 in a teen something to worry about?

An A1C of 5.9 percent, or 6.0, 6.1, or 6.2 percent, all sit in the prediabetes range (5.7 to 6.4 percent). It is a signal worth taking seriously, not a crisis. The first action is to confirm with a repeat A1C plus a fasting glucose or OGTT, since a single A1C value can fluctuate in adolescents. If prediabetes is confirmed, the AAP-recommended response is intensive lifestyle treatment, with pharmacotherapy consideration if labs do not move at the 3 to 6 month re-test.

What is the difference between prediabetes and type 2 diabetes in teens?

Prediabetes means blood sugar is higher than normal but below the diabetes threshold. The American Diabetes Association cutoffs are A1C 5.7 to 6.4 percent, fasting glucose 100 to 125 mg/dL, or 2-hour OGTT 140 to 199 mg/dL. Type 2 diabetes is A1C at or above 6.5 percent, fasting glucose at or above 126 mg/dL, or 2-hour OGTT at or above 200 mg/dL. Both diagnoses require confirmation testing on a different day (a repeat A1C, a fasting glucose, or an OGTT all qualify) before treatment is finalized.

Should my teen be put on metformin if their A1C is high?

Not as the first step. The AAP CPG recommends IHBLT as the first-line foundation. Metformin is the standard pharmacotherapy in pediatric specialty practice when IHBLT alone has not moved labs at the 3 to 6 month re-test and the adolescent meets the CPG age and BMI criteria. The decision is paired with continued IHBLT and made jointly with the family through shared decision-making.

Is Wegovy approved for teen prediabetes?

Wegovy (semaglutide) is FDA approved for chronic weight management in adolescents 12 and older with BMI at or above the 95th percentile. It is not specifically labeled for prediabetes in adolescents. Wegovy carries an FDA boxed warning for medullary thyroid carcinoma seen in rodent studies and is contraindicated in adolescents with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The pediatric obesity medicine specialist will screen for this history before prescribing. The STEP TEENS trial showed substantial BMI reduction in this age group (Weghuber D et al., NEJM 2022). A 2025 secondary analysis examined cardiometabolic and glycemic outcomes (Arslanian SA et al., Diabetes Care 2025). Use in adolescent prediabetes is informed by these data, the AAP CPG, and shared decision-making.

What does an abnormal ALT mean for a teen with high A1C?

A flagged ALT alongside a high A1C often signals MASLD (formerly NAFLD), because both share insulin resistance as the underlying driver. NASPGHAN recommends ALT screening in adolescents with obesity, and the AAP CPG references the same workup. The encouraging part is that the IHBLT lifestyle foundation drives improvement in both A1C and ALT together. Ask the pediatrician for the lab's specific reference range and whether further MASLD evaluation is indicated.

How long does it take to lower a teen's A1C with lifestyle treatment?

The published evidence on IHBLT (adult Diabetes Prevention Program data extended to pediatric intensive-lifestyle cohorts) supports measurable A1C improvement at the 3 to 6 month re-test when 7 to 10 percent weight reduction is achieved, typically 0.2 to 0.5 percentage points. Individual response varies. If labs have not moved at the re-test, the AAP CPG allows pharmacotherapy consideration alongside continued IHBLT for adolescents who meet the age and BMI criteria.

Should my teen see an endocrinologist or a pediatric obesity medicine specialist?

Both pathways are valid. Pediatric endocrinologists are the specialty for diagnosed type 2 diabetes and for complex glycemic management. Pediatric obesity medicine specialists, often DABOM-credentialed, focus on the AAP stepped-care framework including IHBLT delivery, comorbidity workup, and CPG-aligned pharmacotherapy. For prediabetes specifically, a pediatric obesity medicine specialist is usually well aligned with the stepped-care framework.

Is Blueberry Balance covered by insurance for teen prediabetes treatment?

Blueberry Balance is a membership-based pediatric obesity medicine specialty layer. It is not billed through standard health insurance. Most families pay monthly and use HSA and FSA funds where eligible. See the pricing details for the current monthly cost and what is included.

Start a Blueberry Balance visit

This page is for educational purposes and is not a substitute for clinical evaluation. If your teen's lab results indicate a concerning pattern, contact your pediatrician or pediatric specialist directly.

Sources

• Hampl SE et al. Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents with Obesity. Pediatrics. 2023;151(2):e2022060640. doi:10.1542/peds.2022-060640.
• American Diabetes Association. Standards of Care in Diabetes: 2026. Diabetes Care. 2026;49(Suppl 1).
• Vos MB et al. NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children. JPGN. 2017;64:319-334.
• Rinella ME et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. doi:10.1097/HEP.0000000000000520.
• Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS). New England Journal of Medicine. 2022;387:2245-2257.
• Arslanian SA et al. Cardiometabolic and Glycemic Outcomes of Once-Weekly Semaglutide in Adolescents with Obesity: A Secondary Analysis of the STEP TEENS Trial. Diabetes Care. 2025. doi:10.2337/dc25-0824.
• Liu J et al. Trends in Prediabetes Among US Adolescents, 1999 to 2018. JAMA Pediatrics. 2022.
• US Food and Drug Administration. Wegovy (semaglutide) prescribing information. Updated 2022-2026.
• TODAY Study Group. A Clinical Trial to Maintain Glycemic Control in Youth with Type 2 Diabetes. New England Journal of Medicine. 2012;366:2247-2256.